Trybeca-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441).
Hammel, P; Berardi, R; Van Cutsem, E; Feliu, J; Greil, R; Wasan, HS; Metges, JP; Nygren, P; Osterlund, PJ; Parner, V; Seufferlein, T; Gupta, A; Salesse, S; Biswasbaldwin, N; Ibrahim, A; Youssoufian, H; El-Hariry, I; Hidalgo, M J CLIN ONCOL. 2019; 37(4):
Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
Rischin, D; Harrington, KJ; Greil, R; Soulieres, D; Tahara, M; de Castro, G; Psyrri, A; Baste, N; Neupane, PC; Bratland, A; Fuereder, T; Hughes, BGM; Mesia, R; Ngamphaiboon, N; Rordorf, T; Ishak, WZW; Zhang, YY; Jin, F; Gumuscu, B; Burtness, B J CLIN ONCOL. 2019; 37(15):
Tailored dose-dense chemotherapy in combination with trastuzumab as adjuvant therapy for HER2-positive breast cancer: A secondary analysis of the phase III PANTHER trial.
Foukakis, T; Papakonstantinou, A; Matikas, A; Bengtsson, NO; Malmstrom, P; Hedayati, E; Steger, GG; Untch, M; Hubbert, L; Johansson, H; Hellstrom, M; Gnant, M; Loibl, S; Greil, R; Moebus, V; Bergh, JCS J CLIN ONCOL. 2019; 37(15):
Olaratumab plus anthracyline in advanced/metastatic soft tissue sarcoma: Data of real-world utilization in Austria.
Kocher, F; Seeber, A; Weiss, L; Romeder, F; Szkandera, J; Kuhr, T; Kostner, S; Pichler, P; Jager, T; Greil, R; Brodowicz, T J CLIN ONCOL. 2019; 37(15):
REACHAUT: First-line (1L) ribociclib (RIB) plus endocrine therapy (ET) in HR+, HER2-metastatic breast cancer (MBC) in the real-world setting.
Singer, CF; Oehler, L; Egle, D; Greil, R; Petru, E; Balic, M; Marhold, M; Pfeiler, G; Brunner, C; Kwasny, W; Galid, AA; Tinchon, C; Eisterer, W; Haslbauer, F; Hubalek, M; Redl, A; Hock, K; Hennebelle, M; Mraz, B; Steger, GG J CLIN ONCOL. 2019; 37(15):
Differentialdiagnose der Gelenksschwellungen_x000D_
Psenak, O; Fortbildungsseminar für Mediziner; 06.02.2019; Großgmain. 2019.
Vergleich der Hochtontherapie und der TENS Therapie bei chemotherapieinduzierter Polyneuropathie – Projekt HIT-CIPN – Studienprotokoll eines RCT
Johansson, T; Schaffler-Schade, D; Herfert, J; Sassmann, R; Gampenrieder, S; Rinnerthaler, S; Lampl, K; Rieder, F; Flamm, M; Greil, R; Niebauer, J; 53. Kongress für Allgemeinmedizin und Familienmedizin; 12.-.14.09.2019; Erlangen. 2019.
Psoriasis Arthritis
Psenak, O; Fortbildungsseminar; 11.09.2019; Großgmain. 2019.
JAK-Inhibitoren: Fallberichte
Psenak, O; JAK-Expertenmeeting; 17.10.2019; Wien. 2019.
Muskuloskelettale Pathophysiologie
Psenak, O; PMU-Lehre für 3. Jahrgang:_x000D_ Pathophysiologische des muskuloskelettalen Apparates; 08.10.2019; Salzburg. 2019.
